Skip to main content

Research Repository

Advanced Search

Telmisartan to Prevent Recurrent Stroke and Cardiovascular Events

Yusuf, Salim; Diener, Hans-Christoph; Sacco, Ralph L.; Cotton, Daniel; Ounpuu, Stephanie; Lawton, William A.; Palesch, Yuko; Martin, Renée H.; Albers, Gregory W.; Bath, Philip M.W.; Bornstein, Natan; Chan, Bernard P.L.; Chen, Sien-Tsong; Cunha, Luis; Dahlöf, Björn; De Keyser, Jacques; Donnan, Geoffrey A.; Estol, Conrado; Gorelick, Philip; Gu, Vivian; Hermansson, Karin; Hillbrich, Lutz; Kaste, Markku; Lu, Chuanzhen; Machnig, Thomas; Pais, Prem; Roberts, Robin; Skvortsova, Veronika; Teal, Philip; Toni, Danilo; VanderMaelen, Cam; Voight, Thor; Weber, Michael; Yoon, Byung-Woo


Salim Yusuf

Hans-Christoph Diener

Ralph L. Sacco

Daniel Cotton

Stephanie Ounpuu

William A. Lawton

Yuko Palesch

Renée H. Martin

Gregory W. Albers

Stroke Association Professor of Stroke Medicine

Natan Bornstein

Bernard P.L. Chan

Sien-Tsong Chen

Luis Cunha

Björn Dahlöf

Jacques De Keyser

Geoffrey A. Donnan

Conrado Estol

Philip Gorelick

Vivian Gu

Karin Hermansson

Lutz Hillbrich

Markku Kaste

Chuanzhen Lu

Thomas Machnig

Prem Pais

Robin Roberts

Veronika Skvortsova

Philip Teal

Danilo Toni

Cam VanderMaelen

Thor Voight

Michael Weber

Byung-Woo Yoon



Prolonged lowering of blood pressure after a stroke reduces the risk of recurrent stroke. In addition, inhibition of the renin–angiotensin system in high-risk patients reduces the rate of subsequent cardiovascular events, including stroke. However, the effect of lowering of blood pressure with a renin–angiotensin system inhibitor soon after a stroke has not been clearly established. We evaluated the effects of therapy with an angiotensin-receptor blocker, telmisartan, initiated early after a stroke.


In a multicenter trial involving 20,332 patients who recently had an ischemic stroke, we randomly assigned 10,146 to receive telmisartan (80 mg daily) and 10,186 to receive placebo. The primary outcome was recurrent stroke. Secondary outcomes were major cardiovascular events (death from cardiovascular causes, recurrent stroke, myocardial infarction, or new or worsening heart failure) and new-onset diabetes.


The median interval from stroke to randomization was 15 days. During a mean followup of 2.5 years, the mean blood pressure was 3.8/2.0 mm Hg lower in the telmisartan group than in the placebo group. A total of 880 patients (8.7%) in the telmisartan group and 934 patients (9.2%) in the placebo group had a subsequent stroke (hazard ratio in the telmisartan group, 0.95; 95% confidence interval [CI], 0.86 to 1.04; P = 0.23). Major cardiovascular events occurred in 1367 patients (13.5%) in the telmisartan group and 1463 patients (14.4%) in the placebo group (hazard ratio, 0.94; 95% CI, 0.87 to 1.01; P = 0.11). New-onset diabetes occurred in 1.7% of the telmisartan group and 2.1% of the placebo group (hazard ratio, 0.82; 95% CI, 0.65 to 1.04; P = 0.10).


Therapy with telmisartan initiated soon after an ischemic stroke and continued for 2.5 years did not significantly lower the rate of recurrent stroke, major cardiovascular events, or diabetes. ( number, NCT00153062.)


Voigt, T., Hilbrich, L., Bath, P., Martin, R. H., Ôunpuu, S., Yusuf, S., …Yoon, B. (2008). Telmisartan to Prevent Recurrent Stroke and Cardiovascular Events. New England Journal of Medicine, 359(12), 1225-1237.

Journal Article Type Article
Online Publication Date Sep 18, 2008
Publication Date Sep 18, 2008
Deposit Date Sep 11, 2008
Publicly Available Date Sep 11, 2008
Journal New England Journal of Medicine
Print ISSN 0028-4793
Electronic ISSN 1533-4406
Publisher Massachusetts Medical Society
Peer Reviewed Peer Reviewed
Volume 359
Issue 12
Pages 1225-1237
Keywords General Medicine
Public URL
Publisher URL
Copyright Statement Copyright information regarding this work can be found at the following address:


Yusuf_NEJM_20080827.pdf (469 Kb)

Copyright Statement
Copyright information regarding this work can be found at the following address:

You might also like

Downloadable Citations